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Methods: We retrospectively analyzed data from patients with massive and submassive
PE treated with USAT over a 2-year period. EKOS catheters (EkoSonic Endovascular
system, EKOS Corp., Bothell, WA) were placed in the largest lower lobe pulmonary
artery, bilaterally in 14 patients (93%) and unilaterally in 1 patient (7%). Recombinant
t-PA was administered through the EKOS catheters as a 5 mg bolus followed by 1
mg/hour for a maximum dose of 20 mg.
Results: Fifteen patients received USAT for PE between May, 2010 and April, 2012. Ten
patients (67%) presented with saddle emboli. Four patients (27%) presented with massive
PE requiring inotropic support and mechanical ventilation. Technical success in EKOS
catheter placement was 100%. Pre-USAT echocardiographic RV/LV diameter ratios were
obtained in 13 (87%) patients and were abnormal in 12 (92%) patients (mean 1.23 
0.28). After USAT, 5(33%) patients had follow-up echocardiograms, in which the RV/LV
ratio normalized in all patients (mean 0.83  0.06) (p0.07). Mean pulmonary artery
(PA) pressures were 39.9  2.1 before treatment and 31.2  3.2 after treatment (p  0.03).
Three patients (20%) had follow-up angiography, of which 2 (67%) had complete
resolution of emboli. Mean hospital stay was 10.88.59 days. Thirteen patients
(87%) were discharged alive. One patient (7%) required a blood transfusion.
Conclusions: In patients with massive and submassive PE, USAT restores hemodynamic
stability and reverses right ventricular dilatation and with minimal risk of bleeding
complications.
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TCT-760
Mid-term Outcomes of Alcohol Septal Ablation for Obstructive Hypertrophic
Cardiomyopathy in Patients with Sigmoid versus Neutral Ventricular Septum
Josef Veselka1, Pavol Tomasov1, David Zemanek1
12nd Medical School, Charles University, University Hospital Motol, Prague 5,
Czech Republic
Background: The aim of this study was to determine whether the differences in the baseline
septal morphology influenced outcomes of patients after alcohol septal ablation (ASA).
Methods: A total of 100 consecutive, highly symptomatic patients with HOCM and a neutral
or sigmoid septum (74 patients vs 26 patients) underwent ASA and were examined clinically
and echocardiographically at baseline and at follow-up (median 30 months vs 24 months).
Results: At baseline, a neutral septum morphology was associated with a thicker basal
septum [21 (19-24) mm vs 19 (18-20) mm; p0.01] and higher pressure gradient at rest [59
(39-80) mm vs 43 (33-50) mm; p0.01], but a similar pressure gradient after provocation [100
(72-120) mmHg vs 97 (70-110) mmHg; p0.31], and subsequently both resting gradient [10
(10-16) mmHg vs 12 (10-15) mmHg; p0.67] and provoked gradient after ASA [20 (10-30)
mmHg vs 18 (12-25) mmHg; p0.71]. Four patients died during follow-up (4% vs 1%; NS).
Pressure gradient, septum thickness and symptoms decreased significantly in both groups.
Conclusions: Patients treated with ASA who had a sigmoid septum were characterized
at baseline by a thinner basal septum and lower pressure gradient at rest. However, they
showed an identical pressure gradient after provocation and subsequently after ASA. ASA
was safe and effective in both groups of patients.
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Background: Alcohol septal ablation (ASA) is a catheter-based intervention that has
been used as an alternative to surgical myectomy in highly symptomatic patients with
hypertrophic obstructive cardiomyopathy (HOCM). However, clinically relevant compli-
cations can result, including death and complete heart block (CHB) associated with
syncope or resuscitation.This study was designed to evaluate the incidence of major
complications with a focus on CHB after ASA for HOCM.
Methods: This international, multicenter, retrospective study reviewed 545 patients who
were treated using ASA; 421 (77%) met the inclusion criteria for this study. Clinical and
echocardiographic follow-up (3–6 months) was completed in 394 patients (94%).
Results: ASA led to a significant reduction in symptoms and outflow gradient. One
patient (0.2%) died of cardiac tamponade four days after ASA. Two other patients (0.5%)
died several weeks after ASA (sudden death of unknown cause). Sustained ventricular
arrhythmias occurred within hospital stay in three patients (0.7%). A total of 70 patients
(17%) developed mostly transient intra/post-procedural CHB; in 30% of them, CHB
occurred/reoccurred later than 24 hours after ASA. Ninety-seven percent of CHB
occurred until the fifth post-ASA day. Permanent pacemakers for CHB were implanted in
35 patients (8%). Multivariate analysis identified the intra-procedural bundle branch block
and age as independent predictors of CHB.
Conclusions: In this multicenter study, ASA was clinically effective in highly symp-
tomatic patients undergoing a first intervention for HOCM. The most frequent major
post-procedural complication was CHB (17%) that occurred late or recurred in almost
one-third of these cases (5%). Ninety-seven percent of all CHB cases occurred until the
fifth post-procedural day. Independent predictors of its development were intra-procedural
bundle branch block and age of patients. Difficulties in predicting CHB should lead to
close post-procedural monitoring and hospital stays lasting at least 5 days. Generally,
these results highlight the importance of proper interventional training and establishing
complex “HCM centers” as a prerequisite for all institutions offering ASA.
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Impact of left atrial appendage occlusion, with percutaneous device on left
atrial function
Pedro Almeida1, Eduardo Infante de Oliveira1, João Marques1,
Fernando Ribeiro1, Pedro Canas Silva1, Anto´nio Nunes Diogo1, Fausto Pinto1
1Hospital de Santa Maria - CHLN, Lisboa, Lisboa
Background: Favorable results with the occlusion of the left atrial appendage (LAA),
using percutaneous devices, for thromboembolic events prevention, has lead to a
widespread use of this technique. However, the long-term effects on left atrial (LA)
function are unclear. The objective of this study was to evaluate the impact of LAA
occlusion on LA function.
Methods: LAA occlusion by percutaneous femoral access was performed in five female
common swine, in sinus rhythm. TEE evaluation of LA dimensions using 2D, mitral and
pulmonary veins (PV) Doppler flow, and TDI of mitral annular motion was performed at
baseline and after 90 days.
Results: Four animals survived until the 90 days. Weight and body surface area increased
from 53.04.7Kg/1.30.1m2 to 74.11.5Kg/1.60.4m2. At basaline, minimum LA
diameter, area and volume were 22.02.1 mm/m2; 5.60.4cm2/m2 and 12.11.1cm3/
m2. Maximum LA diameter, area and volume were 27.63.7mm/m2;7.81.0cm2/m2
and 19.14.0cm3/m2. At 90 days, systolic diameter, area and volume were
19.52.9mm/m2; 5.50.6cm2/m2 and 13.21.4cm3/m2 and diastolic values were
40.15.6mm/m2; 8.91.5cm2/m2 and 27.16.0cm3/m2. LA ejection fraction signifi-
cantly increased from 359% to 507% at 90 days (p0.038). There was a significant
increase in LA maximal diameter (p0.04) and a trend toward LA maximal volume
increase from baseline to follow-up (p0.082). There was a significant increase of E wave
VTI (p0.024) from 7.40.6cm to 10.51.4cm. TDI of mitral annulus showed E‘, A‘
and S‘ basal velocities of 10.82.7cm/s; 8.42.4cm/s and 8.41.6cm/s with no
significant changes to follow-up. The E/E‘ ratio suffered no significant change, and there
was a trend towards peak A‘ wave velocity (p0.067). Baseline PV flow velocities were:
S 65.02.8cm/s; A 31.08.5cm/s and D 51.07.1cm/s. At 90 days, S, A and D, were
55.04.2cm/s; 21.53.5cm/s and 44.56.4cm/s. The S/D ratio was 1.30.1 at baseline
and 1.30.3 at 90 days. The D velocity at follow-up, revealed a significant reduction
relative to the baseline (p0.049).
Conclusions: This study provides initial evidence that LAA occlusion may not significantly
impair LA function and does not lead to armful atrial remodeling or loss of contractile function.
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Safety and Biocompatibility of the Coherex WaveCrestTM Left Atrial
Appendage Occluder in a 30-Day Canine Study
Yanping Cheng1, Jenn McGregor1, Robert Sommer2, William Gray2,
Daryl Edmiston3, Gerard Conditt1, Genghua Yi1, Armando Tellez1,
Serge Rousselle4, Juan Granada1, Greg Kaluza1
1Cardiovascular Research Foundation, Orangeburg, NY, 2Columbia University
Medical Center, New York, USA, 3Coherex Medical, Salt Lake City, UT, 4Alizée
Pathology, LLC, Thurmont, MD
Background: Left atrial appendage (LAA) occlusion is proposed to reduce the risk of
thromboembolic stroke in atrial fibrillation patients.
Methods: WaveCrestTM (Coherex Medical, Salt Lake City, UT) LAA occluder was
deployed in 6 dogs via transseptal puncture under fluoroscopy and transesophageal
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echocardiography (TEE). After confirming the position by TEE and multi-angle fluoros-
copy, the occluder was released to seal the LAA ostium. Local and systemic histopathol-
ogy was assessed 30 days after device implantation.
Results: By pre-implant angiography and TEE, the mean diameter of LAA ostium was
15.92.5mm and15.82.5mm, respectively. LAA occlusion devices, clinically indicated
for 1420mm human LAA ostial diameter, were successfully implanted in 6 animals
without pericardial effusion or other procedure- or device-related complications. Post-
operative TEE showed all devices in the intended positions achieving successful closure
of all LAA ostia (Figure a). Minimal peri-device leaks ( 3mm jet) were noted in 2/6
cases. Animals experienced no adverse events over 30 days post-implant. Histological
analysis showed adequate deployment and complete circumferential occlusion of all 6
appendages after 30 days. Full endothelial coverage of the luminal aspect of the occluder
was found with no surface thrombosis (Figure b). No adverse histology findings were
noted in the myocardia, mitral valves, kidneys or brains.
Conclusions: In a 30-day canine study the Coherex WaveCrestTM demonstrated safe
deployment, durable LAA occlusion and favorable biocompatibility.
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Background: Left atrial appendage (LAA) occlusion aims to reduce the risk of stroke in
atrial fibrillation patients. In this study, we evaluated the feasibility and long-term safety of the
Ultrasept LAA closure device (Figure a)(Cardia Inc., Eagan, MN) in a canine model.
Methods: Trans-septal puncture and device deployment was guided under fluoroscopy and
transesophageal echo (TEE) in 5 dogs. First, the distal cylindrical bulb was released and
secured to the appendage wall with hooks and then the proximal sail was unfolded and covered
the LAA ostium. Rotational angiography, TEE and histology outcomes were assessed 30 days
following implantation.
Results: Pre-operative TEE showed mean diameter of the LAA ostium 17.21.6mm,
depth 18.51.7mm and landing zone for the distal bulb 12.81.3mm. The mean bulb
diameter implant was 16.81.8 mm. Post-operative TEE showed adequate position and
successful occlusion in all implanted devices. Small pericardial effusion related to
multiple device attempts was noted in 1 animal. At 30 days, TEE showed full occlusion
of all LAA ostia (Figure b) besides a minimal peri-device leak (3mm) in 1 animal. No
pericardial effusion or device-related thrombus formation were found. Histological
analysis confirmed circumferential occlusion of all appendages and complete neointimal
coverage on the luminal aspect of the occluder (Figure c).
Conclusions: The percutaneous delivery of the Ultrasept LAA occlusion device was
feasible and safe in a canine model. At 30 days, all devices displayed complete healing
and occlusion of the LAA without any adverse events.
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Early Safety of the Amplatzer Cardiac Plug™ for Left Atrial Appendage
Occlusion
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Background: Following strong evidence that the left atrial appendage (LAA) is the site
of the majority of thrombus formation within the left atrium in patients with non-valvular
atrial fibrillation, non-pharmacological approaches to LAA exclusion have been devel-
oped and shown to be effective. We aim to assess the cumulative experience of a single
operator using a strict set of deployment and release criteria for the Amplatzer Cardiac
Plug (ACP, St. Jude Medical, Plymouth, MN) and the impact of these criteria on
procedural success and complications.
Methods: Procedural and in-hospital outcomes of LAA occlusion performed by a single
operator using the ACP in 100 anticoagulant ineligible patients with a high stroke risk
were assessed.
Results: One hundred patients with a mean CHADS2 score of 3.211.23 underwent
catheterization for closure of LAA with the ACP. The mean landing zone as assessed by
TEE was 20.013.21 mm, and 20.83.19 mm by fluoroscopy. The mean difference
between the TEE and the fluoroscopic measurements was 0.81.13 mm. Device
deployment was successful in 100/100 attempted cases with a mean deployed device size
of 24.363.27 mm. In 82 of the 100 cases the first device selected was implanted.
Procedural and in-hospital complications were limited to a single case of pericardial
tamponade and one post-procedural pulmonary oedema both of which were adequately
treated with no long-term sequelae.
Conclusions: In this single operator report, LAA occlusion using the double element
ACP can be safely performed with excellent success rates. Using very specific deploy-
ment success, stability and release criteria, this device can achieve LAA occlusion with
extremely low complication rates in an extremely frail oral anticoagulant ineligible
population with multiple co-morbidities.
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Background: Little data exist on the long-term outcomes following LAA closure in
patients with absolute contraindication for warfarin.
Methods: A total of 52 patients (mean age: 74 8 years, median CHADS2 score: 3
[2-4]) underwent LAA closure using the ACP device in 7 Canadian centers. Most patients
received short-term (1-3 months) dual antiplatelet therapy following the procedure and
single antiplatelet therapy thereafter, and no patient was lost to follow-up (12 months in
all patients). Transesophageal echocardiography (TEE) was performed in 74% of patients
at 6-month follow-up. Peridevice residual leak was defined as mild (flow width: 1-3 mm)
or severe (flow width: 3 mm).
Results: The procedure was successful in 98.1% of the patients, and was associated with
a low rate of periprocedural complications (device embolization: 1.9%, no stroke or
pericardial effusion). At a mean follow-up of 20  5 months, the rates of death, stroke,
systemic embolism, severe pericardial effusion, and major bleeding were 5.8%, 1.9%, 0%,
1.9%, and 1.9%, respectively. TEE at follow-up showed the presence of mild peridevice
leak in 16.2% of patients. There were no cases of device thrombosis.
Conclusions: In patients with NVAF at high risk for cardioembolism and absolute
contraindication for anticoagulation, LAA closure using the ACP device followed by
dual/single antiplatelet therapy was associated with a very low rate of cardioembolic and
bleeding events at 2-year follow-up. No cases of severe residual leak or device thrombosis
were observed at 6-month follow-up.
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